Insider trade

CEO received an award of 344K ABT derivative securities

Traded Feb 24, 2026 · Filed Feb 26, 2026

Abbott LaboratoriesABT

344K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 24, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 26, 2026

CEOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001612571-26-000004
Filed / recorded

Feb 26, 2026, 11:21 PM UTC

Added to OQRO

Oct 2, 2026, 12:26 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

ABBOTT LABORATORIES

Issuer CIK

1800

Ticker

ABT

Reporting person

Robert B Ford

Relationship

Director, Officer

Officer title

CHAIRMAN AND CEO

Security

Option (right to buy)

Table

Derivative (Table II)

Transaction date

Feb 24, 2026

Transaction code

A

Shares / units

344,066

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

344,066

Ownership form

Direct

Amendment

No

Footnotes from the filing

Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,688 on February 24, 2027, 114,689 on February 24, 2028, and 114,689 on February 24, 2029.